oxytocin
Trade name: syntocinon
Approved
Apr 17, 1980
More than a century ago, Sir Henry Dale demonstrated that a component of the pituitary causes contractions of the mammalian uterus, hence his coining the term “oxytocic,” derived from the Greek for “quick birth,” for its activity. The discovery that a component of the pituitary causes milk secretion followed within a few years. By 1930, oxytocin was separated from vasopressin into pitocin and pitressin, respectively, at Parke Davis and made available for research. That a single peptide was responsible for these uterine and mammary actions was definitively confirmed upon the sequencing and synthesis of the peptide, 9 amino acids in length. Vincent du Vigneaud was awarded a Nobel Prize for this work. Oxytocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. Oxytocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage. Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+- dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+. Oxytocin has specific receptors in the myometrium and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term. The Oxytocin receptor is a typical class I G protein-coupled receptor that is primarily coupled via G(q) proteins to phospholipase C-beta. The high-affinity receptor state requires both Mg(2+) and cholesterol, which probably function as allosteric modulators. The agonist-binding region of the receptor has been characterized by mutagenesis and molecular modeling and is different from the antagonist binding site. The function and physiological regulation of the Oxytocin system is strongly steroid dependent. — NCATS
Clinical trial activity
623 trials · 341 clinical orgs · 13 marketing orgs
Earliest trial started Jan 1, 2002 (NCT00405158)
Timeline
1980s
- Apr 17, 1980
Novartis — Earliest FDA Approval
- Apr 17, 1980
Novartis — NDA Secondary Org
- Apr 17, 1980
Novartis — NDA Organization
- Apr 29, 1980
West-Ward Pharmaceutical — NDA Secondary Org
- Apr 29, 1980
Hikma — NDA Secondary Org
- Jul 9, 1980
Fresenius — NDA Secondary Org
- Nov 19, 1980
Endo Pharmaceuticals — Marketing Organization
- Nov 19, 1980
Par Pharmaceuticals — NDA Secondary Org
- Nov 19, 1980
PH HEALTH — Marketing Organization
- Mar 29, 1985
Abbott — NDA Secondary Org
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2007
Earliest Phase 3 Sponsor(trial)
- Jan 24, 2008
Teva — Marketing Organization
- Jan 24, 2008
Dr. Reddy's Laboratories — Marketing Organization
2010s
- Feb 13, 2013
Hikma — Marketing Organization
- Jul 13, 2018
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Jul 13, 2018
Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization
Indications
Approved for
Studied for
- Abortion, Induced · Phase 4
- Abortion, Missed · Phase 4
- Acute Pain · Phase 2
- Adenomyosis · Phase 4
- Aging · Phase 2/Phase 3
- Alcohol-Induced Disorders · Phase 2
- Alcoholism · Phase 3
- Alcohol-Related Disorders · Phase 1
- Alcohol Withdrawal Delirium · Phase 2
- Amphetamine · Phase 1
- Analgesia · Phase 4
- Analgesics, Opioid · Phase 1/Phase 2
- Anemia · Phase 4
- Anorexia Nervosa · Early Phase 1
- Antisocial Personality Disorder · Early Phase 1
- Anxiety · Phase 4
- Anxiety Disorders · Phase 4
- Arginine Vasopressin · Phase 2
- Arrhythmias, Cardiac · Phase 4
- Atrophy · Phase 2
- Attention Deficit and Disruptive Behavior Disorders · Phase 2
- Attention Deficit Disorder with Hyperactivity · Early Phase 1
- Autism Spectrum Disorder · Phase 4
- Autistic Disorder · Phase 2
- Behavior · Phase 4
- Binge-Eating Disorder · Phase 2
- Bipolar Disorder · Phase 1
- Blood Loss, Surgical · Phase 4
- Body Dysmorphic Disorders · Phase 2
- Bone Diseases · Phase 2
- Borderline Personality Disorder · Phase 1
- Breast Neoplasms · Early Phase 1
- Bronchiectasis · Phase 4
- Bronchopulmonary Dysplasia · Phase 1
- Carcinoma, Intraductal, Noninfiltrating · Early Phase 1
- Cervical Ripening · Phase 4
- Cesarean Section · Phase 4
- Child Development Disorders, Pervasive · Phase 3
- Chronic Pain · Phase 4
- Cocaine-Related Disorders · Phase 2/Phase 3
- Cocaine Smoking · Phase 1/Phase 2
- Cognition Disorders · Phase 2
- Cold Injury · Phase 2
- Congenital Abnormalities · Early Phase 1
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 2
- Craniopharyngioma · Phase 2
- Cystitis, Interstitial · Phase 4
- Deficiency Diseases · Phase 4
- Delivery, Obstetric · Phase 4
- Depression · Phase 2/Phase 3
- Depression, Postpartum · Phase 2
- Depressive Disorder · Phase 2
- Diabetes Insipidus · Phase 2
- Diabetes Insipidus, Neurogenic · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Investigational · Phase 4
- Drug Therapy · Phase 4
- Dystocia · Phase 4
- Education · Phase 2
- Ehlers-Danlos Syndrome · Phase 1/Phase 2
- Embryo Transfer · Phase 1
- Emotional Intelligence · Phase 2
- Emotions · Phase 1
- Empathy · Phase 4
- Estrogens · Phase 1
- Expressed Emotion · Early Phase 1
- Facial Expression · Early Phase 1
- Family Characteristics · Phase 2
- Fear · Phase 1
- Feeding and Eating Disorders · Phase 1
- Feeding Behavior · Early Phase 1
- Femur · Phase 2
- Fetal Development · Phase 4
- Fragile X Syndrome · Phase 2
- Frontotemporal Dementia · Phase 2
- Gastric Emptying · Early Phase 1
- Genetic Diseases, Inborn · Phase 2
- Growth and Development · Phase 3
- Health · Phase 4
- Healthy Volunteers · Phase 4
- HIV Infections · Phase 2
- Human-Animal Interaction · Phase 2/Phase 3
- Hyperbilirubinemia, Neonatal · Phase 4
- Hyperphagia · Phase 2
- Hypersensitivity · Phase 4
- Hypopituitarism · Phase 4
- Hypotension · Phase 4
- Hypothalamic Diseases · Phase 4
- Infant, Premature · Early Phase 1
- Inflammation · Phase 2
- Interpersonal Relations · Phase 2
- Irritable Mood · Phase 2
- Labor, Induced · Phase 4
- Labor, Obstetric · Phase 4
- Labor Pain · Phase 4
- Leiomyoma · Phase 4
- Loneliness · Phase 1
- Magnetic Resonance Imaging · Early Phase 1
- Major Depressive Disorder · Phase 1
- Memory · Phase 1
- Memory Disorders · Phase 1
- Menopause · Phase 3
- Mental Disorders · Phase 2
- Mental Health Services · Phase 1
- Methadone · Early Phase 1
- Migraine Disorders · Phase 2
- Mood Disorders · Phase 2
- Myocardial Infarction · Phase 2/Phase 3
- Myocardial Ischemia · Phase 4
- Myoma · Phase 4
- Neonatology · Phase 4
- Neuralgia · Phase 2
- Neuroendocrine Tumors · Phase 2
- Obesity · Phase 4
- Obsessive-Compulsive Disorder · Phase 2
- Obstetrics · Phase 3
- Opioid-Related Disorders · Phase 2
- Osteoarthritis · Phase 2/Phase 3
- Osteoarthritis, Knee · Phase 2/Phase 3
- Ovarian Diseases · Phase 2
- Ovulation Induction · Phase 3
- Oxidative Stress · Phase 2
- Oxytocin · Phase 4
- Pain · Phase 4
- Pain Measurement · Phase 1/Phase 2
- Parent-Child Relations · Phase 1
- Parity · Phase 3
- Parturition · Phase 1/Phase 2
- Pediatric Obesity · Phase 2
- Pediatrics · Phase 1/Phase 2
- Pelvic Pain · Phase 2/Phase 3
- Pharmacokinetics · Phase 4
- Phobia, Social · Phase 2
- Pituitary Diseases · Phase 4
- Placebos · Phase 2
- Placenta Previa · Phase 4
- Placenta, Retained · Phase 4
- Polycystic Ovary Syndrome · Phase 3
- Postmenopause · Phase 2/Phase 3
- Postoperative Hemorrhage · Phase 1/Phase 2
- Postoperative Pain · Phase 4
- Postpartum Hemorrhage · Phase 4
- Prader-Willi Syndrome · Phase 3
- Pre-Eclampsia · Phase 3
- Pregnancy · Phase 4
- Pregnancy Complications · Phase 4
- Pregnancy, High-Risk · Early Phase 1
- Pregnancy Trimester, Second · Phase 4
- Premature Rupture of Fetal Membranes · Phase 4
- Premenstrual Dysphoric Disorder · Phase 2/Phase 3
- Primary Prevention · Phase 4
- Psychological Distress · Phase 2
- Psychology, Clinical · Phase 4
- Psychology, Social · Early Phase 1
- Psychotic Disorders · Phase 1
- Recognition, Psychology · Phase 4
- Rotator Cuff Injuries · Phase 2
- Sarcopenia · Phase 1/Phase 2
- Schizophrenia · Phase 4
- Schizotypal Personality Disorder · Phase 1
- Sedentary Behavior · Phase 1/Phase 2
- Sensory Thresholds · Phase 1
- Sexual Dysfunction, Physiological · Phase 2
- Sleep Apnea, Obstructive · Phase 2
- Sleep Apnea Syndromes · Phase 1
- Smoking · Phase 2/Phase 3
- Smoking Cessation · Phase 2/Phase 3
- Social Behavior · Phase 4
- Social Cognition · Phase 2
- Social Interaction · Phase 2
- Social Isolation · Phase 4
- Social Perception · Early Phase 1
- Spinal Stenosis · Phase 2
- Stress Disorders, Post-Traumatic · Phase 4
- Stress, Psychological · Phase 2
- Stroke · Phase 1
- Substance Abuse, Oral · Phase 4
- Substance-Related Disorders · Phase 4
- Sunburn · Phase 2
- Tobacco Smoking · Phase 4
- Tobacco Use Disorder · Phase 4
- Toes · Early Phase 1
- Tranexamic Acid · Phase 3
- Trust · Phase 4
- Umbilical Cord Clamping · Phase 3
- Uterine Inertia · Phase 4
- Uterine Myomectomy · Phase 4
- Uterine Rupture · Phase 1/Phase 2
- Uterus · Phase 3
- Vagina · Phase 2/Phase 3
- Vaginal Diseases · Phase 3
- Vulvar Diseases · Phase 3
- Weight Gain · Phase 2
Mechanism of action
- Oxytocin receptorAGONIST
OXTR agonist
Approval history
- approvedApr 17, 1980
Chemistry & pharmacology
SMILES
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O- Mol. weight
- 1007.21 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- WikipediaOxytocin ↗
- NCATS1JQS135EYN ↗
- ChEMBLCHEMBL395429 ↗
Also known as
- orasthin
- orasthin
- orasthin
- oxymetrin
- oxystin
- oxytocin
- oxytocin
- oxytocin
- oxytocin
- oxytocin
- oxytocin
- oxytocin
- oxytocin
- oxytocin
- oxytocin
- oxytocin
- oxytoine
- partocon
- perlacton
- pitocin
- pitocin
- pitocin
- synthetic oxytocin
- syntocinon
- syntocinon
- syntocinon
- syntometrine
- syntometrine
- syntometrine
- vagitocin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07053774 | Phase 2 | Nov 5, 2025 | Atrium Medical Center, Wake Forest University |
| NCT06968481 | Phase 2 | Oct 1, 2025 | Insud Pharma |
| NCT07188207 | N/A | Oct 1, 2025 | Assiut University |
| NCT07140237 | Early Phase 1 (Phase 1) | Sep 30, 2025 | University of Electronic Science and Technology of China |
| NCT06930391 | N/A | Sep 15, 2025 | Icahn School of Medicine at Mount Sinai |
| NCT07162584 | N/A | Sep 13, 2025 | University of Electronic Science and Technology of China |
| NCT07265180 | N/A | Sep 8, 2025 | Humboldt University |
| NCT07119398 | Phase 4 | Jul 14, 2025 | Eastern Virginia Medical School |
| NCT07006896 | N/A | Jul 10, 2025 | University of Pennsylvania |
| NCT06990217 | Phase 4 | Jun 30, 2025 | Emek Medical Center |
| NCT07093060 | Early Phase 1 (Phase 1) | Jun 9, 2025 | University of Electronic Science and Technology of China |
| NCT06945926 | Phase 2 | Jun 1, 2025 | Zhejiang University |
| NCT06881459 | N/A | Mar 25, 2025 | University of Copenhagen |
| NCT06808516 | Phase 2 | Feb 28, 2025 | University of Basel |
| NCT06676774 | Phase 2 | Jan 10, 2025 | University of Basel |
| NCT06651476 | Phase 2 | Dec 31, 2024 | National Institute of Neurological Disorders and Stroke (NINDS), Wake Forest University |
| NCT06364228 | Phase 2 | Nov 30, 2024 | University of Nebraska |
| NCT06580782 | Phase 4 | Nov 18, 2024 | Cornell University |
| NCT06550089 | Phase 2 | Oct 31, 2024 | Medical College of Wisconsin, University of Chicago |
| NCT06333340 | N/A | Oct 31, 2024 | Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Canada |
Organizations
Research & Development (341)
Marketing (18)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abbott | For profit | NDA2 | Mar 29, 1985 |
| Asklepion | For profit | NDA2 | — |
| Dr. Reddy's Laboratories | For profit | MKTG | Jan 24, 2008 |
| Endo Pharmaceuticals | For profit | MKTG | Nov 19, 1980 |
| Fresenius | For profit | NDA2 | Jul 9, 1980 |
| Hikma | For profit | MKTG | Feb 13, 2013 |
| Hikma | For profit | SYN | Apr 29, 1980 |
| Hikma | For profit | SYN | Apr 29, 1980 |
| Hikma | For profit | NDA2 | Apr 29, 1980 |
| Nichi-Iko Pharmaceutical Co., Ltd. | For profit | MKTG | Jul 13, 2018 |
| Novartis | For profit | NDA2 | Apr 17, 1980 |
| Novartis | For profit | NDA | Apr 17, 1980 |
| PH HEALTH | For profit | MKTG | Nov 19, 1980 |
| Par Pharmaceuticals | For profit | NDA2 | Nov 19, 1980 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Jul 13, 2018 |
| Sagent Pharmaceuticals, Inc. | For profit | SYN | Jul 13, 2018 |
| Teva | For profit | MKTG | Jan 24, 2008 |
| West-Ward Pharmaceutical | For profit | NDA2 | Apr 29, 1980 |